Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 17/11/2017
SIETES contiene 92128 citas

 
 
 1 a 19 de 19 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Poluzzi E, Diemberger I, de Ridder M, Koci A, Clo M, Oteri A, Pecchioli S, Bezemer I, Schink T, Ulrichsen SP, Boriani G, Sturkenboom MCJ, De Ponti F, Trifirò G. Use of antihistamines and risk of ventricular tachyarrhythmia: a nested case-control study in five European countries from the ARITMO project. Eur J Clin Pharmacol 2017;73:1499-510. [Ref.ID 102126]
2. Cita con resumen
Hawkes N. Statin initiation is unrelated to cardiovascular risk score, finds study.. BMJ 2017;359:j4898. [Ref.ID 102110]
3. Cita con resumen
Zhang F, Mamtani R, Scott FI, Goldberg DS, Haynes K, Lewis JD. Increasing use of prescription drugs in the United Kingdom. Pharmacoepidemiol Drug Saf 2016;25:628-36. [Ref.ID 100019]
4. Cita con resumen
Strom BL, Schinnar R, Karlawish J, Hennessy S, Teal V, Bilker WB. Statin therapy and risk of acute memory impairment. JAMA Intern Med 2015;175:1399-405. [Ref.ID 99143]
5. Cita con resumen
Gaist D, Wallander M-A, González-Pérez A, García-Rodríguez LA. Incidence of hemorrhagic stroke in the general population: validation of data from The Health Improvement Network. Pharmacoepidemiol Drug Saf 2013;22:176-82. [Ref.ID 94868]
7. Cita con resumen
Lapi F, Nicotra F, Scotti L, Vannacci A, Thompson M, Pieri F, Mugelli N, Zambon A, Corrao G, Mugelli A, Rubino A. Use of antidepressant sertoninergic medications and cardiac valvulopathy: a nested case-control study in the health improvement network (THIN) database. Br J Clin Pharmacol 2012;74:536-44. [Ref.ID 93708]
10.Tiene citas relacionadas
McGorrian C, Blake GJ. The risks in risk prediction. BMJ 2012;345:9. [Ref.ID 93501]
11. Cita con resumen
Wise BL, Peloquin C, Choi H, Lane NE, Zhang Y. Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders. Am J Med 2012;125:e23-28. [Ref.ID 93278]
12. Cita con resumen
Anónimo. Risque de cancers chez des patients diabétiques traités par insuline glargine?. Prescrire 2010;30:268-70. [Ref.ID 88326]
13. Cita con resumen
Lo Re III V, Haynes K, Forde KA, Localio AR, Schiinnar R, Lewis JD. Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection. Pharmacoepidemiol Drug Saf 2009;18:807-14. [Ref.ID 86561]
14. Cita con resumen
Haynes K, Forde KA, Schinnar R, Wong P, Strom BL, Lewis JD. Cancer incidence in The Health Improvement Network. Pharmacoepidemiol Drug Saf 2009;18:730-6. [Ref.ID 86510]
15.Enlace a cita originalTiene citas relacionadas Cita con resumen
Currie CJ, Poole CD, Gale EAM. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-77. [Ref.ID 86107]
16.Enlace a cita originalTiene citas relacionadas Cita con resumen
Smith U, Gale EAM. Does diabetes therapy influence the risk of cancer?. Diabetologia 2009;52:1699-708. [Ref.ID 86102]
17.Enlace a cita original
Hall GC. Validation of death and suicide recording on the THIN UK primary care database. Pharmacoepidemiol Drug Saf 2009;18:120-31. [Ref.ID 85254]
18. Cita con resumen
Jara M, Lanes SF, Wentworth III C, May C, Kesten S. Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database. Drug Saf 2007;30:1151-60. [Ref.ID 81829]
19. Cita con resumen
Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007;16:393-401. [Ref.ID 79964]
Seleccionar todas
 
 1 a 19 de 19